Report cover image

Vasopressin for Vasoplegic Shock Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032

Publisher Fortune Business Insights Pvt. Ltd.
Published Jan 01, 2025
Length 146 Pages
SKU # FOB19472485

Description

Vasopressin for Vasoplegic Shock Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2024-2032



Growth Factors of Vasopressin for Vasoplegic Shock Market

The vasopressin for vasoplegic shock market size was valued at USD 890.9 million in 2019, and the market is now projected to grow USD 2657.9 million in 2027 exhibiting a CAGR of 14.8% during the forecast period of 2020-2027.

The vasopressin for vasoplegic shock market has been benefited by COVID-19 due to an increase in demand for the product owing to the rising cases. SARS is associated with increased prevalence of new or worsening cardiac disease, making vasopressin drugs important for infected patient. Therefore, there are more attentions on the supply and development of these treatments in the pharmaceutical industry. This demand spike has made the industry focus on the use of vasopressin in handling cardiac cases related to COVID-19.

There are more on-goings of cardiac surgeries, particularly CABG where vasopressin is used in managing blood flow not to result in sepsis. Currently 340000 CABG procedures are done annually in the United States of America and Vasoplegic Shock is a common complication. With these surgeries trending, there will be an uptake in demand for vasopressin for vasoplegic shock. This trend proves the importance of vasopressin in addressing some challenges that crop up with cardiac surgeries.

Vasoplegia develops in myocardial, septic, anaphylactic, and distributive shock; many pathways bear on the vascular substrate precise cardiac myocyte. Therefore, with increasing knowledge of these processes, approaches to the treatment of Sepsis are now becoming oriented to the individual twoand three-dimensional multiple therapies using various vasopressors. The constantly rising number of double-blind, randomized clinical trials assessing the efficacy of vasopressin in patients with critical illness and septic shock will also contribute to market growth. It is anticipated that this research will help to enhance and define the function of vasopressin in the treatment of vasoplegic shock.

Comprehensive Analysis of Vasopressin for Vasoplegic Shock Market

The vasopressin for vasoplegic shock market growth is rising at an exponential rate due to its market segmentation. This market expansion rightly provides a thorough market breakdown near to the industry considering the leading supply and demand forces. These segmentations are methodically segregated by application analysis. By application analysis includes sepsis, post-cardiac surgery, and others.

The North America region lead the vasopressin for vasoplegic shock market share by benefitting a market size of USD 561.3 million in 2019 due to increasing prevalence of sepsis across the region.

The top players in the markets have a central responsibility in the healthcare industry to be sure of industrial prospectus development and to establish the market norms. These players include, Endo International plc, AMOMED Pharma, La Jolla Pharmaceutical Company, Pfizer Inc., Ferring Pharmaceuticals, Fresenius Kabi Canada, Astellas Pharma, Eagle Pharmaceuticals, Inc. these market players provide a level-playing competitive landscape.

In April 2020, AMOMED Pharma announced the development of arginine vasopressin injection for treating septic shock in COVID-19 infected patients.

Segmentation Table

ATTRIBUTES DETAILS

Study Period 2016-2027

Base Year 2019

Forecast Period 2020-2027

Historical Period 2016-2018

Unit Value (USD Million)

Segmentation

By Application

Sepsis

Post Cardiac Surgery

Others

By Geography

North America (By Application and By Country)

The U.S. (By Application)

Canada (By Application)

Europe (By Application and By Country)

Germany (By Application)

UK (By Application)

France (By Application)

Italy (By Application)

Spain (By Application)

Scandinavia (By Application)

Rest of Europe (By Application)

Asia Pacific (By Application and By Country)

China (By Application)

India (By Application)

Japan (By Application)

Australia (By Application)

Southeast Asia (By Application)

Rest of Asia Pacific (By Application)

Latin America (By Application and By Country)

Brazil (By Application)

Mexico (By Application)

Rest of Latin America (By Application)

The Middle East & Africa (By Application and By Country)

South Africa (By Application)

Gcc Countries (By Application)

Rest of Middle East & Africa (By Application)Please Note: It will take 5-6 business days to complete the report upon order confirmation.

Table of Contents

146 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
4. Key Insights
4.1. Recent Industry Developments Such as Mergers & Acquisitions
4.2. Regulatory Scenario for Key Countries
4.3. New Product Launch
4.4. Statistics on Prevalence of Cardiac Disorders for Key Countries/Regions
4.5. Pipeline Analysis
5. Global Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
5.1. Key Findings / Summary
5.2. Market Analysis, Insights and Forecast – By Application
5.2.1. Sepsis
5.2.2. Post Cardiac Surgery
5.2.3. Others
5.3. Market Analysis, Insights and Forecast – By Region
5.3.1. North America
5.3.2. Europe
5.3.3. Asia Pacific
5.3.4. Latin America
5.3.5. Middle East & Africa
6. North America Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
6.1. Key Findings / Summary
6.2. Market Analysis, Insights and Forecast - By Application
6.2.1. Sepsis
6.2.2. Post Cardiac Surgery
6.2.3. Others
6.3. Market Analysis, Insights and Forecast - By Country
6.3.1. U.S.
6.3.2. Canada
7. Europe Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
7.1. Key Findings / Summary
7.2. Market Analysis, Insights and Forecast - By Application
7.2.1. Sepsis
7.2.2. Post Cardiac Surgery
7.2.3. Others
7.3. Market Analysis, Insights and Forecast - By Country/Sub Region
7.3.1. U.K.
7.3.2. Germany
7.3.3. France
7.3.4. Spain
7.3.5. Italy
7.3.6. Scandinavia
7.3.7. Rest of Europe
8. Asia Pacific Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
8.1. Key Findings / Summary
8.2. Market Analysis, Insights and Forecast - By Application
8.2.1. Sepsis
8.2.2. Post Cardiac Surgery
8.2.3. Others
8.3. Market Analysis, Insights and Forecast - By Country/Sub Region
8.3.1. Japan
8.3.2. China
8.3.3. India
8.3.4. Australia
8.3.5. Southeast Asia
8.3.6. Rest of Asia Pacific
9. Latin America Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
9.1. Key Findings / Summary
9.2. Market Analysis, Insights and Forecast - By Application
9.2.1. Sepsis
9.2.2. Post Cardiac Surgery
9.2.3. Others
9.3. Market Analysis, Insights and Forecast - By Country/Sub Region
9.3.1. Brazil
9.3.2. Mexico
9.3.3. Rest of Latin America
10. Middle East & Africa Vasopressin for Vasoplegic Shock Market Analysis, Insights and Forecast, 2016-2027
10.1. Key Findings / Summary
10.2. Market Analysis, Insights and Forecast - By Application
10.2.1. Sepsis
10.2.2. Post Cardiac Surgery
10.2.3. Others
10.3. Market Analysis, Insights and Forecast - By Country/Sub Region
10.3.1. GCC Countries
10.3.2. South Africa
10.3.3. Rest of Middle East & Africa
11. Competitive Analysis
11.1. Key Industry Developments
11.2. Global Market Share Analysis (2019)
11.3. Competition Dashboard
11.4. Comparative Analysis – Major Players
11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
11.5.1. Endo International plc
11.5.1.1. Overview
11.5.1.2. Products & services
11.5.1.3. SWOT analysis
11.5.1.4. Recent developments
11.5.1.5. strategies
11.5.1.6. financials (based on availability)
11.5.2. AMOMED Pharma
11.5.2.1. Overview
11.5.2.2. Products & services
11.5.2.3. SWOT analysis
11.5.2.4. Recent developments
11.5.2.5. strategies
11.5.2.6. financials (based on availability)
11.5.3. La Jolla Pharmaceutical Company
11.5.3.1. Overview
11.5.3.2. Products & services
11.5.3.3. SWOT analysis
11.5.3.4. Recent developments
11.5.3.5. strategies
11.5.3.6. financials (based on availability)
11.5.4. Pfizer Inc.
11.5.4.1. Overview
11.5.4.2. Products & services
11.5.4.3. SWOT analysis
11.5.4.4. Recent developments
11.5.4.5. strategies
11.5.4.6. financials (based on availability)
11.5.5. Ferring Pharmaceuticals
11.5.5.1. Overview
11.5.5.2. Products & services
11.5.5.3. SWOT analysis
11.5.5.4. Recent developments
11.5.5.5. strategies
11.5.5.6. financials (based on availability)
11.5.6. Fresenius Kabi Canada
11.5.6.1. Overview
11.5.6.2. Products & services
11.5.6.3. SWOT analysis
11.5.6.4. Recent developments
11.5.6.5. strategies
11.5.6.6. financials (based on availability)
11.5.7. Astellas Pharma
11.5.7.1. Overview
11.5.7.2. Products & services
11.5.7.3. SWOT analysis
11.5.7.4. Recent developments
11.5.7.5. strategies
11.5.7.6. financials (based on availability)
11.5.8. Eagle Pharmaceuticals, Inc.
11.5.8.1. Overview
11.5.8.2. Products & services
11.5.8.3. SWOT analysis
11.5.8.4. Recent developments
11.5.8.5. strategies
11.5.8.6. financials (based on availability)
11.5.9. Others
11.5.9.1. Overview
11.5.9.2. Products & services
11.5.9.3. SWOT analysis
11.5.9.4. Recent developments
11.5.9.5. strategies
11.5.9.6. financials (based on availability)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us